Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (211-220 of 311) with videos related to

Pageof 32
Sort By:
Cancer Chemotherapy and Pharmacology|September 16, 2008
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
The Lancet. Oncology|August 18, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialSophie Leboulleux, Lars Bastholt, Thomas Krause, et al.
Cancers|March 13, 2024
Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial CancerKyukwang Kim, Negar Khazan, Rachael B Rowswell-Turner, et al.
Breast Cancer Research and Treatment|May 10, 2019
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)Christel Fontaine, Vincent Renard, Heidi Van den Bulk, et al.
Investigational New Drugs|March 22, 2015
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityAhmad Awada, Herlinde Dumez, Philippe G Aftimos, et al.
Frontiers in Oncology|December 26, 2022
Identification of <i>HMGA2</i> as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancerAlexander Spira, Ahmad Awada, Nicolas Isambert, et al.
Springerplus|July 22, 2016
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trialJavier Cortés, Hope S Rugo, Chris Twelves, et al.
British Journal of Cancer|December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursDebbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
Gynecologic Oncology|June 17, 2023
Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancerNnamdi I Gwacham, Karolina A Kilowski, Fernando O Recio, et al.
BMC Cancer|November 25, 2010
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphomaLaetitia Gerlier, Mark Lamotte, Ahmad Awada, et al.
Pageof 32

Showing results (211-220 of 311) with videos related to

Sort By:
Pageof 32
Cancer Chemotherapy and Pharmacology|September 16, 2008
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
The Lancet. Oncology|August 18, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialSophie Leboulleux, Lars Bastholt, Thomas Krause, et al.
Cancers|March 13, 2024
Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial CancerKyukwang Kim, Negar Khazan, Rachael B Rowswell-Turner, et al.
Breast Cancer Research and Treatment|May 10, 2019
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)Christel Fontaine, Vincent Renard, Heidi Van den Bulk, et al.
Investigational New Drugs|March 22, 2015
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityAhmad Awada, Herlinde Dumez, Philippe G Aftimos, et al.
Frontiers in Oncology|December 26, 2022
Identification of <i>HMGA2</i> as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancerAlexander Spira, Ahmad Awada, Nicolas Isambert, et al.
Springerplus|July 22, 2016
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trialJavier Cortés, Hope S Rugo, Chris Twelves, et al.
British Journal of Cancer|December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursDebbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
Gynecologic Oncology|June 17, 2023
Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancerNnamdi I Gwacham, Karolina A Kilowski, Fernando O Recio, et al.
BMC Cancer|November 25, 2010
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphomaLaetitia Gerlier, Mark Lamotte, Ahmad Awada, et al.
Pageof 32